Drug-Drug Interactions in Patients Co-infected With HCV and HIV.
作者信息
Nozaki Yuichi, Yanase Mikio, Masaki Naohiko
机构信息
Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan.
Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan.
出版信息
JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618.
PMID:26172899
Abstract
摘要
相似文献
1
Drug-Drug Interactions in Patients Co-infected With HCV and HIV.
JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618.
2
Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.
JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621.
3
Are we hopefully very close to the end of HCV?
Turk J Gastroenterol. 2014 Apr;25(2):230-1. doi: 10.5152/tjg.2014.0009.
4
Hepatitis C and HIV co-infection: closing the gaps.
JAMA. 2015;313(12):1217-8. doi: 10.1001/jama.2015.1111.
5
Therapy for hepatitis C--the costs of success.
N Engl J Med. 2014 Apr 17;370(16):1552-3. doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11.
6
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2.
7
Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.
J Antimicrob Chemother. 2017 Oct 1;72(10):2955-2958. doi: 10.1093/jac/dkx222.
8
Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):329. doi: 10.1038/nrgastro.2014.64. Epub 2014 Apr 29.
9
New Indications for Harvoni.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):6.
10
Assessing a broader user base for new HCV drug.
Lancet Infect Dis. 2015 Apr;15(4):383. doi: 10.1016/S1473-3099(15)70119-2.
Zotero 插件